原文始发于微信公众号(药时代):新药研发不易!蓝鸟(Bluebird Bio)暂停LentiGlobin基因疗法1/2、3期临床研究
药时代编者按:
请允许我们用这首歌曲表达我们忧伤的心情。
今天,我们都是一只小小的蓝鸟,
都是一个蓝鸟人!
项目继续进行!
(图片来源:蓝鸟公司官网)
bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)
In line with the clinical study protocols for HGB-206 and HGB-210, bluebird bio placed the studies on temporary suspension following a report received last week that a patient who was treated more than five years ago in
No cases of hematologic malignancy have been reported in any patient who has received treatment with betibeglogene autotemcel for transfusion-dependent β-thalassemia (licensed as ZYNTEGLOin the
“The safety of every patient who has participated in our studies or is treated with our gene therapies is the utmost priority for us,” said
The independent safety review board monitoring the company’s studies as well as the
Investor Conference Call Information
bluebird bio will hold a conference call to discuss this update on
To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website athttp://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the event.
About HGB-206 and HGB-210
HGB-206 is an ongoing, Phase 1/2 open-label study designed to evaluate the efficacy and safety of LentiGlobin gene therapy for sickle cell disease (SCD) that includes three treatment cohorts: Groups A, B and C. A refined manufacturing process designed to increase vector copy number (VCN) and further protocol refinements made to improve engraftment potential of gene-modified stem cells were used for Group C. Group C patients also received LentiGlobin for SCD made from HSCs collected from peripheral blood after mobilization with plerixafor, rather than via bone marrow harvest, which was used in Groups A and B of HGB-206.
HGB-210 is an ongoing Phase 3 single-arm open-label study designed to evaluate the efficacy and safety of LentiGlobin gene therapy for SCD in patients between two years and 50 years of age with sickle cell disease.
About LentiGlobin for SCD (bb1111)
LentiGlobin gene therapy for sickle cell disease (bb1111) is an investigational treatment being studied as a potential treatment for SCD. bluebird bio’s clinical development program for LentiGlobin for SCD includes the completed Phase 1/2 HGB-205 study, the ongoing Phase 1/2 HGB-206 study, and the ongoing Phase 3 HGB-210 study.
The
LentiGlobin for SCD received orphan medicinal product designation from the
bluebird bio is conducting a long-term safety and efficacy follow-up study (LTF-307) for people who have participated in bluebird bio-sponsored clinical studies of LentiGlobin for SCD. For more information visit:https://www.bluebirdbio.com/our-science/clinical-trialsorclinicaltrials.govand use identifier NCT04628585 for LTF-307.
LentiGlobin for SCD is investigational and has not been approved in any geography.
About ZYNTEGLO (betibeglogene autotemcel)
Betibeglogene autotemcel (beti-cel) is a one-time gene therapy that adds functional copies of a modified form of the β-globin gene (βA-T87Q-globin gene) into a patient’s own hematopoietic (blood) stem cells (HSCs). Once a patient has the βA-T87Q-globin gene, they have the potential to produce HbAT87Q, which is gene therapy-derived adult Hb, at levels that may eliminate or significantly reduce the need for transfusions. In studies of beti-cel, transfusion independence (TI) is defined as no longer needing red blood cell transfusions for at least 12 months while maintaining a weighted average Hb of at least 9 g/dL.
The
Non-serious adverse events (AEs) observed during clinical studies that were attributed to beti-cel included abdominal pain, thrombocytopenia, leukopenia, neutropenia, hot flush, dyspnea, pain in extremity, tachycardia and non-cardiac chest pain. One serious adverse event (SAE) of thrombocytopenia was considered possibly related to beti-cel.
Additional AEs observed in clinical studies were consistent with the known side effects of HSC collection and bone marrow ablation with busulfan, including SAEs of veno-occlusive disease.
For details, please see the Summary of Product Characteristics (SmPC).
On
The
bluebird bio is conducting a long-term safety and efficacy follow-up study, LTF-303 for people who have participated in bluebird bio-sponsored clinical studies of ZYNTEGLO.
About bluebird bio, Inc.
bluebird bio is pioneering gene therapy with purpose. From our
bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders: cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma, using gene and cell therapy technologies including gene addition, and (megaTAL-enabled) gene editing.
bluebird bio has additional nests in


-
中国好BD|天境生物(I-Mab Biopharma) -
中国好BD|基石药业(CSTONE PHARMACEUTICALS) -
中国好投资人 | 倚锋资本投资的优秀企业(上篇) -
启明系 | 启明创投投资的优秀企业(中) -
启明系 | 启明创投投资的优秀企业(上) -
歌曲 | PD-1之歌(附:100篇PD-1/PD-L1相关好文章) -
LAV系|礼来亚洲基金投资的优秀企业(上) -
LAV系|礼来亚洲基金投资的优秀企业(中) -
中国好VC!LAV系|礼来亚洲基金投资的优秀企业(下) -
中国好BD | 百济神州(BeiGene) -
中国好BD|再鼎医药(Zai Lab) -
和黄医药自主研发肿瘤药苏泰达®正式上市,中国创新药惠及非胰腺神经内分泌瘤患者! -
默沙东停止开发两款在研新冠疫苗,将继续全力开发两款新冠新药PD-1携手CAR-T疗法!强强联合能否打破实体瘤治疗困局? -
新元医疗一期基金被投公司Kymab以11亿美金首付款被赛诺菲收购 -
新冠病人的嗅觉与味觉失灵,是短暂还是持久的? -
请查收!以创新促进健康,2020年FDA新药审批报告 -
TRK成新药研发热门靶标 -
送你一朵小红花!2020年中国乘风破浪的改良型新药创新型企业 -
中国新药研发,我要“送你一朵小红花”! -
Keytruda的故事 -
请查收!以创新促进健康,2020年FDA新药审批报告 -
送您Keytruda最新说明书(97页)!送白衣天使一朵小红花! -
2025年全球畅销药TOP10预测:Keytruda位居榜首,225亿美元 -
纪念斯隆-凯特琳癌症中心研究:通过恢复“预警系统”提高肿瘤免疫疗法疗效 -
EGFR三代靶向药物有哪些?未来靶向治疗思路是什么? -
谢雨礼博士 | 生物医药2021:把握创新转型的大势



发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权